Preoperative tumor markers as prognostic factors of colorectal liver metastases

Hepato-Gastroenterology

Volumn 56, Issue 90, 2009, Pages 317-320

  Treska, V ^a,b   Topolcan, O ^a   Stanislav, K ^a   Liska, Vaclav ^a   Holubec, L ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b University Hospital and Medical Faculty ^*  (Czech Republic)

Author keywords

Liver surgery; Patients prognosis; Preoperative tumor markers; Radiofrequency ablation

Indexed keywords

ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; THYMIDINE KINASE; TISSUE POLYPEPTIDE ANTIGEN; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE INTERVAL; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION;

CATHETER ABLATION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 67649213197     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Yamaguchi M, Yamanoi A, Igaroshi M, et al: A resected case of liver metastasis from colon cancer that occured 13 years after a colectomy. Hepatogastroenterology2008; 55:2221-3.
2. Vyhnaek F, Denemark L, Ducbac V, et al: Anatomical resection for liver metastases of the carcinoma of the large intestine and the rectum. Rozhl Chir. 2005; 84(l):28-32 (in Czech with English abstract).
3. Ma C J, Hsieh JS, Wang WM, et al: Multivariate analysis of prognostic determinants for colorectal cancer patients with high preoperative serum CEA levels: prognostic value of postoperative serum CEA levels. Kaohsiung J. Med. Sci. 2006; 22:604- 609.
4. Boonpipattanapong T, Chewatanakornkul S: Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. J Clin Gastroenterol. 2006; 40:592-595.
5. Park YA, Sohn SK, Seong J, et al: Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol. 2006; 93:145-150.
6. Yamamoto M, Maehara Y, Sakaguchi Y, et al: Distributions in CEA doubling time differ in patients with recurrent colorectal carcinomas. Hepatogastroenterology2004; 51:147-151.
7. Desch CE, Benson AB, Smith TJ, et al: Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol. 1999; 17:1312.
8. Plebani M, De Paoli M, Basso D, et al: Serum tumor markers in colorectal cancer staging, grading, and follow-up. J Surg Oncol. 1996; 62:239-244.
9. Locker GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24:5313-5327.
10. Mansour O, Motawi T, Khaled H, et al: Clinical value of thymidine kinase and tissue polypeptide specific antigen in breast cancer. Dis Markers. 1993;11:171-177.
11. Thomas WM, Robertson JF, McKenna PG, et al: Serum thymidine kinase in colorectal neoplasia. Eur J Surg Oncol. 1995; 21:632-634.
12. Holubec L Jr, Topolcan O, Pikner R, et al: Criteria for the selection of referential groups in tumor marker statistical evaluation on the basis of a retrospective study. Anti-cancer Res. 2003; 23:865-870.
13. Mishaeli M, Klein B, Sadikov E, et al: Initial TPS serum level as an indicator of relapse and survival in colorectal cancer. Anticancer Res. 1998; 18:2101-2105.
14. Lindmark G, Bergstrom R, Pahlman L, et al: The association of preoperative serum tumor markers with Dukes' stage and survival in colorectal cancer. Br J Cancer. 1995; 71:1090-1094.
15. Kornek G, Schenk T, Raderer M, et al: Tissue polypep-tide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumors. Br J Cancer. 1995; 71:182-185.
16. Safranek J, Holubec L, Topolcan O, et al: Expression of mRNA MMP-7 and mRNA TIMP-1 in non-small cell lung cancer. Anticancer Res 2007; 27: 2953-2959.
17. Finek J, Holubec L Jr, Topolcan O, et al: Clinical relevance of tumor markers for the control of chemotherapy. Anticancer Res. 2005; 25(3A): 1655-8.
18. Topolcan O, Holubec L Jr, Finek J, et al: Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy Anticancer Res. 2005; 25(3A):1831-3.
19. Holubec L Jr, Topolcan O, Pikner R, et al: The significance of CEA, CA19-9 and CA72-4 in the detection of col orectal carcinoma recurrence.Anticancer Res. 2000 20(6D):5237-44.
20. Liska V, Treska V, Holubec L, et al: Prognostic factors of early recurrence of colorectal liver metastases and their usage in clinical praxis. Rozhl Chir. 2006; 85(4):163-8. Review. Czech, (in Czech with English abstract).
21. Liska V, Treska V, Holubec L Jr, et al: A partial relaps of a colorectal carcinoma metastatic process following liver surgery-a multifactorical study. Rozhl Chir. 2006 Feb;85(2):86-9. Czech, (in Czech with English abstract).
22. Carpelan-Holmstrom M, Haglund C, Lundin J, et al: Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer. Br J Cancer. 1996; 74: 925-929.
23. Gonzalez-Quintela A, Mallo N, Mella C, et al: Serum levels of cytokeratin-18 (tissue polypeptide-specific antigen) in liver diseases. Liver Int. 2006;26(10):1217-24.
24. Gonzalez-Quintela A, Garcia J, Campos J, et al: Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19. Alcohol. 2006; 38(l):45-9.
25. Treska V, Skalicky T, Finek J, et al: Is liver resection or radiofrequency ablation indicated in breast carcinoma metastases? Rozhl Chir. 2004; 83(4):173-7. Czech, (in Czech with English abstract).
26. Finek J, Holubec L Jr, Topolcan O, et al: Clinical importance of determination of tumor markers during follow-up in breast carcinoma Cas Lek Cesk. 2004; 143(3): 174-7. Czech, (in Czech with English abstract).
27. Yasui K, Shimizu Y, Hirai T, et al: Surgical treatment for colorectal liver metastases-results of multi-institute study for effects of radical hepatectomy. Gan To Kagaku Ryoho. 2004; 31:690-694.
28. Goldstein MJ, Mitchell EP: Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005; 2 3:338-351.
29. Kijima M, Togo S, Ichikawa Y, et al: Clinical significance of serum CEA protein and CEA mRNA after resection of colorectal liver metastases. Anticancer Res. 2005; 25:1327-1332.
30. Holdenrieder S, Holubec L Jr, Topolcan O, et al: Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy. Anticancer Res. 2005; 25(3A):1795-801.
31. Wang JY, Lu CY, Chu KS, et al: Prognostic Significance of Pre- and Postoperative Serum Carcinoembryonic Antigen Levels in Patients with Colorectal Cancer. Eur Surg Res. 2007 23; 39(4):245-250.
32. Grossmann I, de Bock GH, Meershoek-Klein Kranen-barg WM, et al: Carcinoembryonic antigen (CEA) measurement during follow-up for rectal carcinoma is useful even if normal levels exist before surgery. A retrospective study of CEA values in the TME trial. Eur J Surg Oncol. 2007; 33(2):183-7.